The trademark application BRIUMVI was filed by TG Therapeutics, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on April 26, 2021, and it was registered by office on August 3, 2021 without any oppositions.
The application was filed in English (German was selected as the second language).
Total Surrender of the trademark registration was recorded on October 29, 2021.